The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Vaginal microbicides and the prevention of HIV transmission
Open accessAbstract
Worldwide, nearly half of all individuals living with HIV are now women, who acquire the virus largely by heterosexual exposure. With an HIV vaccine likely to be years away, topical microbicide formulations applied vaginally or rectally are being investigated as another strategy for HIV prevention. A review of preclinical and clinical research on the development of microbicides formulated to prevent vaginal HIV transmission yielded 118 studies: 73 preclinical and 45 clinical. Preclinical research included in-vitro assays and cervical explant models, as well as animal models. Clinical research included phase I and II/IIb safety studies, and phase III efficacy studies. Whereas most phase I and phase II clinical trials have found microbicide compounds to be safe and well tolerated, phase III trials completed to date have not demonstrated efficacy in preventing HIV transmission. Topical microbicides are grouped into five classes of agents, based on where they disrupt the pathway of sexual transmission of HIV. These classes include surfactants/membrane disruptors, vaginal milieu protectors, viral entry inhibitors, reverse transcriptase inhibitors, and a fifth group whose mechanism is unknown. The trajectory of microbicide development has been toward agents that block more specific virus—host cell interactions. Microbicide clinical trials face scientifically and ethically complex issues, such as the choice of placebo gel, the potential for viral resistance, and the inclusion of HIV-infected participants. Assessment of combination agents will most likely advance this field of research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60312-2 · Cited by 2,292
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60313-4 · Cited by 2,226
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
Wawer, M. J., Gray, R. H., Sewankambo, N. K., Serwadda, D., Li, X., Laeyendecker, O., Kiwanuka, N., Kigozi, G., Kiddugavu, M., Lutalo, T., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429411 · Cited by 1,258
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.
Feldblum, P. J., Adeiga, A., Bakare, R., Wevill, S., Lendvay, A., Obadaki, F., Olayemi, M. O., Wang, L., Nanda, K., & Rountree, W. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001474 · Cited by 280
Target cells in vaginal HIV transmission
Miller, C. J., & Shattock, R. J. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(02)00056-4 · Cited by 220
Cited by
Baggaley, R. F., White, R. G., & Boily, M.-C. (2010) · International Journal of Epidemiology · doi:10.1093/ije/dyq057 · Cited by 713
de Béthune, M.-P. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.09.008 · Cited by 401
Secondary immunodeficiencies, including HIV infection
Chinen, J., & Shearer, W. T. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.040 · Cited by 305
Properties, Chemistry, and Applications of the Bioactive Polysaccharide Curdlan
Zhang, R., & Edgar, K. J. (2014) · Biomacromolecules · doi:10.1021/bm500038g · Cited by 303
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection
Steinbach, J. M., Weller, C. E., Booth, C. J., & Saltzman, W. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.008 · Cited by 113
Metadata
- Authors
- Cutler, B., & Justman, J.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 8
- Issue
- 11
- Pages
- 685-697
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2167246391
- Cited by
- 169
- References
- 5
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vaginal microbicides and the prevention of HIV transmission. https://app.cochat.ai/papers/10.1016/s1473-3099(08)70254-8
- The paper
- Cutler, B., & Justman, J. (2008). Vaginal microbicides and the prevention of HIV transmission. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(08)70254-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.